natgillin/translations-raw huggingface dataset:
No dose adjustment of Harvoni or efavirenz/ emtricitabine/ tenofovir disoproxil fumarate is required. 
Odmerka zdravila Harvoni ali efavirenza/ emtricitabina/ dizoproksiltenofovirat fumarata ni treba prilagajati.
The following adverse drug reactions have been identified with Harvoni (Table 4). 
Pri uporabi zdravila Harvoni so ugotovili naslednje neželene učinke zdravila (preglednica 4).
Outcome for patients without SVR On-treatment virologic failure Relapse b 
Izid za bolnike brez SVR Virološki neuspeh med zdravljenjem Relapsb
When given with elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil fumarate, Harvoni is expected to increase the concentration of tenofovir. 
Pri uporabi z elvitegravirjem/ kobicistatom/ emtricitabinom/ dizoproksiltenofovirat fumaratom se pričakuje, da bo zdravilo Harvoni povečalo koncentracijo tenofovirja.
Following treatment with ledipasvir/sofosbuvir with ribavirin for 12 weeks in post-liver transplant patients with compensated liver disease (SOLAR-1), none (n = 8) of the patients with baseline NS5A RAVs conferring a ledipasvir fold-change of > 100 relapsed. 
Po 12-tedenskem zdravljenju z ledipasvirjem/sofosbuvirjem z ribavirinom pri bolnikih po presaditvi jeter s kompenzirano jetrno boleznijo (SOLAR-1) niso pri nobenem (n = 8) od bolnikov z izhodiščnimi RAV NS5A, ki so doprinesle k > 100-kratni spremembi dovzetnosti za ledipasvir, opazili relapsa.
No target organs of toxicity were identified in rat and dog studies with ledipasvir at AUC exposures approximately 7 times the human exposure at the recommended clinical dose. 
Ledipasvir V študijah ledipasvirja na podganah in psih z izpostavljenostjo AUC, ki je bila približno 7-krat večja od izpostavljenosti pri človeku pri priporočenem kliničnem odmerku, niso opredelili ciljnih organov za toksičnost.
Ciclosporin (600 mg single dose)/ sofosbuvir (400 mg single dose) 
Ciklosporin (600 mg enkratni odmerek)/ sofosbuvir (400 mg enkratni odmerek)
Harvoni contains sunset yellow FCF aluminium lake (E110) 
Zdravilo Harvoni vsebuje barvilo sončno rumeno FCF (E110)
Table 10: Response rates in study ION-1 LDV/SOF 
Preglednica 10: Stopnje odziva v študiji ION-1 LDV/SOF
ORAL CONTRACEPTIVES Norgestimate/ ethinyl estradiol (norgestimate 0.180 mg/ 0.215 mg/ 0.25 mg/ ethinyl estradiol 0.025 mg)/ ledipasvir (90 mg once daily) 
↔ AUC 1,00 (0,87; 1,13) PERORALNI KONTRACEPTIVI Norgestimat/ etinilestradiol (norgestimat 0,180 mg/ 0,215 mg/ 0,25 mg/ etinilestradiol 0,025 mg)/ ledipasvir (90 mg enkrat na dan)
IL28CC genotype FibroTest-Determined Metavir score b 
Rezultat Metavir, določen s testom FibroTest b
H2-receptor antagonists may be administered simultaneously with or staggered from Harvoni at a dose that does not exceed doses comparable to famotidine 40 mg twice daily. 
Antagoniste receptorjev H2 se lahko uporablja sočasno z zdravilom Harvoni ali ločeno v odmerku,
Table 7: Response rates in study ION-3 LDV/SOF 
Preglednica 7: Stopnje odziva v študiji ION-3 LDV/SOF
In vitro resistance selection and cross-resistance studies indicate ledipasvir targets NS5A as its mode of action. 
da ledipasvir cilja NS5A kot njegov način delovanja.
Genotype 1b 0.004 Genotype 2a 
Genotip 1a IL28CC genotip
PHARMACEUTICAL FORM AND CONTENTS 28 film-coated tablets. 
FARMACEVTSKA OBLIKA IN VSEBINA 28 filmsko obloženih tablet 84 (3 plastenke po 28) filmsko obloženih tablet
Tacrolimus (5 mg single dose)/ sofosbuvir (400 mg single dose) 
Takrolimus (5 mg enkratni odmerek)/ sofosbuvir (400 mg enkratni odmerek)h
Population pharmacokinetics analysis in HCV-infected patients indicated that cirrhosis had no clinically relevant effect on the exposure to sofosbuvir and GS-331007. 
Analiza populacijske farmakokinetike pri bolnikih, okuženih s HCV, je pokazala, da ciroza ni imela klinično pomembnega učinka na izpostavljenost sofosbuvirju in
Table 12: Response rates in study ION-2 LDV/SOF 
Preglednica 12: Stopnje odziva v študiji ION-2 LDV/SOF
Relapse b 
Relapsb
If you forget to take Harvoni It is important not to miss a dose of this medicine. 
Če ste pozabili vzeti zdravilo Harvoni
Prior HCV therapy 
Bolniki s CHC genotipa 3
Outcome for patients without SVR On-treatment virologic failure 0/215 Relapsea 
Izid za bolnike brez SVR Virološki neuspeh med zdravljenjem Relapsa
Elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil fumarate (150 mg/ 150 mg/ 200 mg/ 300 mg once daily)/ ledipasvir (90 mg once daily) 
Elvitegravir/ kobicistat/emtricitabin/ dizoproksiltenofovirat fumarat (150 mg/ 150 mg/ 200 mg/ 300 mg enkrat na dan)/ ledipasvir (90 mg enkrat na dan)c/ sofosbuvir (400 mg enkrat na dan)
Post-transplant 
Po presaditvi
In study ION-4, 13 HCV/HIV-1 co-infected patients with genotype 1, including 1 cirrhotic patient, who had failed a sofosbuvir + ribavirin regimen were enrolled; the SVR was 100% (13/13) after 12 weeks of treatment with ledipasvir/sofosbuvir. 
1 bolnikom s cirozo, pri katerih režim s sofobuvirjem + ribavirinom ni bil uspešen; po 12 tednih zdravljenja z ledipasvirjem/sofobuvirjem je bil SVR 100 % (13/13).
Pravastating 
Dojenje
Proton pump inhibitors Omeprazole (20 mg once daily)/ ledipasvir (90 mg single dose)c/ sofosbuvir (400 mg single dose) 
Omeprazol (20 mg enkrat na dan)/ ledipasvir (90 mg enkratni odmerek)c/ sofosbuvir (400 mg enkratni odmerek)c
Cases of severe bradycardia and heart block have been observed when Harvoni is used with concomitant amiodarone with or without other drugs that lower heart rate. 
Pri uporabi zdravila Harvoni s sočasno uporabo amiodarona, skupaj z drugimi zdravili, ki upočasnjujejo srčni utrip, ali brez njih, so opazili primere hude bradikardije in srčnega bloka.
NS5A transient replicons 
Stabilni replikoni prehodni replikoni NS5A mediana (razpon)
HCV protease inhibitor + PEG-IFN+RBV 
PEG-IFN+RBV
No effect = 1.00. b. All interaction studies conducted in healthy volunteers. 
Ni učinka = 1,00 b. Vse študije interakcij so opravili pri zdravih prostovoljcih c. Uporabljeno kot zdravilo Harvoni d. Območje 70-143 %, znotraj katerega ni farmakokinetičnih interakcij e. To so zdravila v razredu, kjer je bilo mogoče predvideti podobne interakcije.
Harvoni is contraindicated with rifampicin, a potent intestinal P-gp inducer (see section 4.3). 
Zdravilo Harvoni je kontraindicirano z rifampicinom, ki je močan induktor P-gp v črevesju
Darunavir boosted with ritonavir (800 mg/ 100 mg once daily) + emtricitabine/ tenofovir disoproxil fumarate (200 mg/ 300 mg once daily)/ ledipasvir (90 mg once daily)c/ sofosbuvir (400 mg once daily)c, d 
Z ritonavirjem okrepljeni darunavir (800 mg/ 100 mg enkrat na dan) + emtricitabin/ dizoproksiltenofovirat fumarat (200 mg/ 300 mg enkrat na dan)/ ledipasvir (90 mg enkrat na dan)
Atazanavir boosted with ritonavir (300 mg/ 100 mg once daily) + emtricitabine/ tenofovir disoproxil fumarate (200 mg/ 300 mg once daily)/ ledipasvir (90 mg once daily)c/ sofosbuvir (400 mg once daily)c, d 
Z ritonavirjem okrepljeni atazanavir (300 mg/ 100 mg enkrat na dan) + emtricitabin/ dizoproksiltenofovirat fumarat (200 mg/ 300 mg enkrat na dan)/ ledipasvir (90 mg enkrat na dan)
Hepatic impairment 
zelo pogosti glavobol
Stable replicons 
Genotip replikonov
No dose adjustment of Harvoni is required for patients with mild or moderate renal impairment. 
Pri bolnikih z blago ali zmerno ledvično okvaro odmerka zdravila Harvoni ni treba prilagajati.
No dose adjustment of Harvoni or ciclosporin is required. 
Odmerka zdravila Harvoni ali ciklosporina ni treba prilagajati.
Tenofovir ↑ Cmax 1.64 (1.54, 1.74) ↑ AUC 1.50 (1.42, 1.59) ↑ Cmin 1.59 (1.49, 1.70) 
Ledipasvir ↑ Cmax 1,63 (1,51; 1,75) ↑ AUC 1,78 (1,64; 1,94) ↑ Cmin 1,91 (1,76; 2,08)
↑ Statins 
Harvoni
IL28CC genotype FibroTest-Determined Metavir scoreb 
Rezultat Metavir, določen s testom FibroTestb
In vitro data indicate that ledipasvir may be a weak inducer of metabolising enzymes such as CYP3A4, CYP2C and UGT1A1. 
kot so CYP3A4, CYP2C in UGT1A1.
Other b 
Ne a b b
Based on the population pharmacokinetic analysis in HCV-infected patients, geometric mean steady-state AUC0-24 for ledipasvir (n = 2,113), sofosbuvir (n = 1,542), and GS-331007 (n = 2,113) were 7,290, 1,320 and 12,000 ng•h/mL, respectively. 
(n = 1.542) oz. GS-331007 (n = 2.113) kot sledi: 7.290, 1.320 oz. 12.000 ng•h/ml.
No dose adjustment of Harvoni or tacrolimus is required. 
Odmerka zdravila Harvoni ali takrolimusa ni treba prilagajati.
As Harvoni contains ledipasvir and sofosbuvir, any interactions that have been identified with these active substances individually may occur with Harvoni. 
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Zdravilo Harvonivsebuje ledipasvir in sofosbuvir, zato se pri uporabi zdravila Harvonilahko pojavijo katere koli interakcije, ki so jih opazili pri uporabi teh posameznih zdravilnih učinkovin.
Co-administration of Harvoni with tipranavir (ritonavir boosted) is expected to decrease the concentration of ledipasvir, leading to reduced therapeutic effect of Harvoni. 
Harvoni s tipranavirjem (okrepljenim z ritonavirjem) zmanjšalo koncentracijo ledipasvirja,
HIV ANTIVIRAL AGENTS: REVERSE TRANSCRIPTASE INHIBITORS Efavirenz/ emtricitabine/ tenofovir disoproxil fumarate (600 mg/ 200 mg/ 300 mg/ once daily)/ ledipasvir (90 mg once daily) 
PROTIVIRUSNA ZDRAVILA PROTI HIV: ZAVIRALCI REVERZNE TRANSKRIPTAZE Efavirenz/ emtricitabin/ dizoproksiltenofovirat fumarat (600 mg/ 200 mg/ 300 mg/ enkrat na dan)/ ledipasvir (90 mg enkrat na dan)c/ sofosbuvir (400 mg enkrat na dan)c, d
NS 
Z
Titanium dioxide 
Zaviralci protonske črpalke
Emtricitabine ↔ Cmax 1.02 (0.96, 1.08) ↔ AUC 1.04 (1.00, 1.08) ↔ Cmin 1.03 (0.97, 1.10) 
Ledipasvir ↔ Cmax 1,11 (0,99; 1,24) ↔ AUC 1,12 (1,00; 1,25) ↔ Cmin 1,17 (1,04; 1,31)
Patient population* 
Dispozicija bolnika
However, it is not recommended that ribavirin be increased to the originally assigned dose (1,000 mg to 1,200 mg daily). 
Prilagajanje odmerka ribavirina pri bolnikih, ki jemljejo 1.000-1.200 mg na dan
Genotype 1a a 
Ravni HCV RNA ob izhodišču a
Ledipasvir 
↑ Lopinavir
No Yes a. One patient was excluded from the LDV/SOF 12-week treatment arm and one patient was excluded from the LDV/SOF+RBV 24-week treatment arm as both patients were infected with genotype 4 CHC. 
Ne Da a. En bolnik iz skupine 12-tedenskega zdravljenja z LDV/SOF in en bolnik iz skupine 24-tedenskega zdravljenja z
↔ Cmin 1.07 (0.89, 1.28) 
↔ Cmax 0,97 (0,83; 1,14)
Yes d 
Ne d f
Emtricitabine ↔ Cmax 1.08 (0.97, 1.21) 
↔ Cmin 0,91 (0,83; 0,99) Emtricitabin ↔ Cmax 1,08 (0,97; 1,21)
↔ Cmin 1.12 (1.05, 1.20) Ledipasvir ↔ Cmax 1.10 (1.01, 1.19) 
↔ Cmin 1,08 (0,98; 1,20) Ritonavir ↔ Cmax 1,17 (1,01; 1,35)
Esomeprazolee 
Okskarbazepin
• palpitations 
• zasoplost
The safety of these vaccines should continue to be carefully monitored. 
Varnost teh zdravil je treba še naprej skrbno spremljati.
On 09 July 2015 the European Commission therefore triggered a procedure under Article 20 of Regulation (EC) No 726/2004 resulting from pharmacovigilance data, and requested the EMA to assess these concerns. 
Zato je 9. julija 2015 Evropska komisija na podlagi farmakovigilančnih podatkov sprožila postopek v skladu s členom 20 Uredbe (ES) št. 726/2004 in zahtevala od agencije EMA, da oceni omenjene pomisleke.
The vast majority of POTS reports came from a centre in Denmark (Brinth et al, 2015)1. 
Velika večina poročil o sindromu POTS izhaja iz centra na Danskem (Brinth idr., 2015)1.
POTS is a systemic syndrome which has been known for a long time under different names and is still poorly understood. 
Sindrom POTS je sistemski sindrom, ki je pod različnimi imeni znan že dolgo časa in je še vedno slabo razumljen.
• The Pharmacovigilance Risk Assessment Committee (PRAC) considered the procedure under Article 20 of Regulation (EC) No 726/2004 for HPV vaccines. 
• Odbor za oceno tveganja na področju farmakovigilance (PRAC) je upošteval postopek v skladu s členom 20 Uredbe (ES) št. 726/2004 o cepivih proti virusu HPV;
In this respect, the CHMP commented that these comparisons should take into account likely increasing awareness of these syndromes to ensure appropriate interpretation of emerging data. 
V zvezi s tem je odbor CHMP pripomnil, da bo treba pri teh primerjavah upoštevati verjetno naraščajočo prepoznavnost teh sindromov, s čimer se zagotovi ustrezna interpretacija dobljenih podatkov.
The benefits of HPV vaccines continue to outweigh their risks. 
Koristi cepiv proti virusu HPV so še vedno večje od tveganj.
Human papillomavirus (HPV) vaccines have been authorised in the European Union since 2006 for the prevention of cervical and various other cancers caused by HPV infection. 
Cepiva proti humanemu papilomavirusu (HPV) so v Evropski uniji od leta 2006 odobrena za preprečevanje raka materničnega vratu in drugih vrst raka, ki jih povzroča okužba s HPV.
The onset of symptoms of CRPS is difficult to define because the syndrome is usually only diagnosed from the point when normal recovery from the initiating trauma should have occurred, and is usually only recognised sometime later among those with continuing pain afterwards. 
Pojav simptomov sindroma CRPS je težko opredeliti, saj se sindrom po navadi diagnosticira šele tedaj, ko bi moralo po začetni travmi priti do okrevanja, in se običajno prepozna šele pozneje pri tistih, ki še vedno trpijo zaradi stalne bolečine.
2 Donegan K, Beau-Lejdstrom R, King B, Seabroke S, Thomson A, Bryan P. Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. 
Donegan K, Beau-Lejdstrom R, King B, Seabroke S, Thomson A, Bryan P. Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK (Bivalentno cepivo proti humanemu papilomavirusu in tveganje za sindrome utrujenosti pri deklicah v Združenem kraljestvu).
This is in accordance with the Scientific advisory group conclusions that most of the reviewed reports of POTS could better correspond to the definition of CFS or at least include some features of CFS. 
To je v skladu z zaključki znanstvene svetovalne skupine, po katerih večina pregledanih poročil o sindromu POTS bolj ustreza opredelitvi sindroma CFS oziroma vsaj vključuje nekatere značilnosti sindroma CFS.
As many of the reports considered in the review have features of CFS and some patients had diagnoses of both POTS and CFS, these results were considered relevant for the current evaluation. 
Ker številna poročila, zajeta v pregledu, vključujejo značilnosti sindroma CFS, nekateri bolniki pa imajo diagnozo sindromov POTS in CFS, so bili ti rezultati pomembni za trenutno ocenjevanje.
Use of these vaccines is expected to prevent many cases of cervical cancer and various other cancers and conditions caused by HPV. 
Pričakuje se, da se z uporabo teh cepiv preprečijo številni primeri raka materničnega vratu in drugih vrst raka ter bolezni, ki jih povzroča virus HPV.
The PRAC noted that some symptoms of these syndromes may overlap with chronic fatigue syndrome (CFS, also known as myalgic encephalomyelitis or ME). 
Odpor PRAC je poudaril, da se nekateri simptomi teh sindromov lahko prekrivajo s sindromom kronične utrujenosti (CFS, znanim tudi kot mialgični encefalomielitis oziroma ME).
• The PRAC took note of the fact that CRPS and POTS occur in the general unvaccinated population and have been described in the medical literature before HPV vaccines were introduced. 
• odbor PRAC se je seznanil z dejstvom, da se sindroma CRPS in POTS pojavljata tudi v splošnem, necepljenem prebivalstvu in da sta bila opisana v medicinski literaturi že pred uvedbo cepiv proti virusu HPV;
POTS patients typically show persistent tachycardia for more than 10 minutes upon standing, as well as an increase in heart rate to above 120 bpm or by ≥ 30bpm, and in children and juveniles below 19 years of age by ≥ 40bpm, without arterial hypotension. 
Pri bolnikih s sindromom POTS se praviloma pojavita trajna tahikardija, ki traja več kot 10 minut po vstajanju, in povečanje srčnega utripa na več kot 120/min ali za ≥ 30/min ter pri otrocih in mladostnikih, mlajših od 19 let, za ≥ 40/min, brez arterijske hipotenzije.
This included the responses submitted by the marketing authorisation holders, published literature, Eudravigilance data, and the outcome of the Scientific advisory group (SAG) on vaccines as well as data submitted by member states and information submitted by the public. 
Podatki so vključevali tudi odgovore imetnikov dovoljenja za promet z zdravilom, objavljeno literaturo, podatke iz sistema Eudravigilance in zaključke znanstvene svetovalne skupine (SAG) o cepivih ter podatke, ki so jih predložile države članice, in informacije, ki jih je posredovala javnost;
A study by Donegan and colleagues (2013)2, using self-controlled case series design (and therefore avoiding the issue of differential diagnostic practice in vaccinated and unvaccinated), evaluated diagnoses of CFS, as well as referrals from general practice for as yet undiagnosed symptoms of chronic fatigue and exhaustion, as well as diagnoses for fibromyalgia, post viral syndrome and neurasthenia. 
V študiji, ki je je opravil Donegan s sodelavci (2013)2, v kateri je uporabil zasnovo s samonadzorovano serijo primerov (in se tako izognil vprašanju diferencialne diagnostične prakse pri cepljenih in necepljenih), so ocenjevali diagnoze sindroma CFS in napotitve osebnih zdravnikov zaradi še nediagnosticiranih simptomov kronične utrujenosti in izčrpanosti ter diagnoz fibromialgije, postvirusnega sindroma n nevrastenije.
The review found no evidence that the overall rates of these syndromes in vaccinated girls were different from expected rates in these age groups, even taking into account possible underreporting. 
S pregledom niso dokazali, da se pojavnost sindromov pri cepljenih deklicah razlikuje od pričakovane pojavnosti v tej starostni skupini, tudi z upoštevanjem morebitnega pomanjkljivega poročanja.
The SAG also concluded that most of the reports of CRPS under review did not appear to fulfil the established diagnostic criteria for CRPS. 
Skupina SAG je zaključila tudi, da večina pregledanih poročil o sindromu CRPS ni izpolnjevala uveljavljenih diagnostičnih kriterijev za sindrom CRPS.
The PRAC requested data and analyses from the MAHs regarding CRPS and POTS from clinical trials and post-marketing safety data, and took into account literature review, data from Eudravigilance, reports submitted by member states, including Denmark, as well as information from Japan and information submitted voluntarily by the public. 
Odbor PRAC je od imetnikov dovoljenja za promet z zdravili zahteval podatke in analize o sindromih CRPS in POTS iz kliničnih preskušanj in podatke o varnosti iz obdobja trženja ter je upošteval pregled literature, podatke iz sistema Eudravigilance, poročila, ki so jih predložile države članice, vključno z Dansko, ter informacije z Japonske in podatke, ki jih je prostovoljno posredovala javnost.
This centre has recently published more information on these reports, suggesting that some of these individuals were likely to have had chronic fatigue syndrome (CFS). 
Iz tega centra so nedavno objavili več informacij o teh poročilih, ki kažejo, da imajo nekatere osebe verjetno sindrom kronične utrujenosti (ang.
Overall, in these analyses the rates of these syndromes in vaccinated girls were consistent with expected rates in these age groups. 
Skupno je bila pojavnost sindromov v teh analizah pri cepljenih deklicah skladna s pričakovano pojavnostjo v tej starostni skupini;
CRPS typically follows an episode of trauma including fracture of the wrist or carpal tunnel syndrome surgery, or immobilisation of the limb. 
Sindrom CRPS praviloma sledi epizodi travme, vključno z zlomom zapestja ali s kirurškim posegom pri sindromu karpalnega kanala, ali imobilizaciji okončine.
Analyses of observed versus expected number of spontaneous reports were undertaken, covering a wide range of scenarios regarding underreporting (from 1 - 100 % reporting) and including reports that did not fully meet the diagnostic criteria for the syndrome. 
Opravili so analize dejanskega števila spontanih poročil v primerjavi s pričakovanim številom in pri tem zajeli širši spekter scenarijev pomanjkljivega poročanja (v razponu med 1- in 100-odstotnim poročanjem) ter vključili poročila, ki niso popolnoma ustrezala diagnostičnim kriterijem za sindrom.
In the review of clinical trial data a total of 60,594 subjects were included for Gardasil/Silgard and Gardasil 9 and 42,047 subjects for Cervarix. 
Pri pregledu podatkov iz kliničnih preskušanj je bilo vključenih 60 594 preiskovank, cepljenih s cepivom Gardasil/Silgard in Gardasil 9, ter 42 047 preiskovank, cepljenih s cepivom Cervarix.
• The PRAC also noted that many of the reviewed reports of POTS had features in common with chronic fatigue syndrome (CFS). 
• odbor PRAC je tudi ugotovil, da so imela številna pregledana poročila o sindromu POTS skupne značilnosti s sindromom kronične utrujenosti (CFS).
It was agreed that employing broad search strategies to identify possible cases of CRPS and POTS and ongoing comparison of reporting rates against available information on the known epidemiology of CRPS and POTS is important. 
Dogovorjeno je bilo, da sta uporaba razširjenih iskalnih strategij za prepoznavanje morebitnih primerov sindromov CRPS in POTS ter stalno primerjanje pogostnosti navedb z razpoložljivimi informacijami o znani epidemiologiji sindromov CRPS in POTS pomembni.
• The PRAC considered that the observed versus expected analyses took into account a wide range of scenarios regarding underreporting and included reports that did not fully meet the diagnostic criteria for the syndromes. 
• odbor PRAC je presodil, da so analize primerjave med dejansko in pričakovano pojavnostjo upoštevale širok spekter scenarijev glede pomanjkljivega poročanja in da so vključevale poročila, ki niso v celoti izpolnjevala diagnostičnih kriterijev za sindroma.
Brinth LS, Pors K, Theibel AC, Mehlsen J. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papillomavirus; Vaccine, 2015; 33(22):2602-5. 
Brinth LS, Pors K, Theibel AC, Mehlsen J. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papillomavirus (Ortostatska intoleranca in sindrom posturalne tahikardije kot domnevni neželeni učinek cepljenja proti humanemu papilomavirusu).
The advice of the Scientific advisory group (SAG) on vaccines was sought; the expertise of this group was supplemented with additional European experts on these syndromes and on neurology, cardiology and pharmacoepidemiology. 
Izkušnje te skupine so dopolnili z izkušnjami drugih evropskih strokovnjakov za ta sindroma ter strokovnjakov za nevrologijo, kardiologijo in farmakoepidemiologijo.
CRPS is defined as continuing pain that is disproportionate to the inciting event and may be associated with dysautonomic signs and symptoms and is usually confined to a single limb. 
Sindrom CRPS je opredeljen kot stalna bolečina, nesorazmerna z dogodkom, ki jo je izzval, in je lahko povezan z znaki in simptomi okvare avtonomnega živčevja ter je običajno omejen na eno okončino.
A diagnosis of POTS cannot solely rely on these criteria; other symptoms (e.g. syncope, fatigue, headaches, lightheadedness, diaphoresis, tremor, palpitations, exercise intolerance, near syncope upon standing upright) vary across patients and are otherwise non-specific. 
Drugi simptomi (npr. sinkopa, utrujenost, glavoboli, vrtoglavica, diaforeza, tremor, palpitacije, zmanjšana telesna zmogljivost, delna sinkopa ob vstajanju) se med bolniki razlikujejo in so nespecifični.
Taking into account the totality of the available information the PRAC concluded that the evidence does not support that HPV vaccines (Cervarix, Gardasil, Gardasil 9, Silgard) cause CRPS or POTS. 
Z upoštevanjem vseh razpoložljivih informacij je odbor PRAC zaključil, da ni dokazov, da cepiva proti virusu HPV (Cervarix, Gardasil, Gardasil 9, Silgard) povzročajo sindrom CRPS ali POTS.